具有无限亲和力的抗体用于体内追踪基因工程淋巴细胞
本研究将DAbR1报告基因导入人原代T细胞及1928z CAR T细胞,用放射性标记的AABD进行体外摄取和体内PET/SPECT显像,发现DAbR1阳性T细胞对86Y-AABD摄取较未转导细胞增加8倍以上,86Y-AABD在DAbR1阳性T细胞中滞留而正常组织持续清除,177Lu-AABD对聚集T细胞群的选择性体内清除似乎可行。
要点
- DAbR1阳性T细胞和CAR T细胞对86Y-AABD的体外摄取较未转导细胞增加8倍以上。
- 86Y-AABD被DAbR1阳性T细胞滞留,同时从正常组织持续清除,可实现静脉给药CAR T细胞的体内追踪。
- 177Lu-AABD对聚集T细胞群的选择性体内清除似乎可行。
核心结论
- 首次证明T细胞可用DAbR1修饰,从而通过PET和SPECT实现体内追踪。
- 观察到的良好生物分布和高图像对比度值得对这种新报告基因进一步研究。
研究设计与样本
- 将DAbR1与绿色荧光蛋白一起亚克隆入SFG逆转录病毒载体,转导CD3/CD28激活的人原代T细胞和第二代1928z CAR T细胞。
- 通过放射性标记AABD的细胞摄取研究确认DAbR1的细胞表面表达。
- 研究静脉注射86Y/177Lu-AABD后DAbR1阳性T细胞体内显像的可行性并测定辐射剂量。
主要发现
- 一组表达DAbR1的T细胞和CAR T细胞在体外对86Y-AABD的摄取较未转导细胞增加8倍以上。
- 显像研究显示86Y-AABD被DAbR1阳性T细胞滞留,同时从正常组织持续清除,从而可实现静脉给药CAR T细胞的体内追踪。
- 正常器官剂量估算有利于重复PET/CT研究。
- 用177Lu-AABD对聚集T细胞群进行选择性体内清除似乎可行。
局限性
- 观察到的良好生物分布和高图像对比度值得对这种新报告基因进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There remains an urgent need for the noninvasive tracking of transfused chimeric antigen receptor (CAR) T cells to determine their biodistribution, viability, expansion, and antitumor functionality. DOTA antibody reporter 1 (DAbR1) comprises a single-chain fragment of the antilanthanoid-DOTA antibody 2D12.5/G54C fused to the human CD4-transmembrane domain and binds irreversibly to lanthanoid (S)-2-(4-acrylamidobenzyl)-DOTA (AABD). The aim of this study was to investigate whether DAbR1 can be expressed on lymphocytes and used as a reporter gene as well as a suicide gene for therapy of immune-related adverse effects. Methods: DAbR1 was subcloned together with green fluorescent protein into an SFG-retroviral vector and used to transduce CD3/CD28-activated primary human T cells and second-generation 1928z (CAR) T cells. Cell surface expression of DAbR1 was confirmed by cell uptake studies with radiolabeled AABD. In addition, the feasibility of imaging of DAbR1-positive T cells in vivo after intravenous injection of 86Y/177Lu-AABD was studied and radiation doses determined. Results: A panel of DAbR1-expressing T cells and CAR T cells exhibited greater than 8-fold increased uptake of 86Y-AABD in vitro when compared with nontransduced cells. Imaging studies showed 86Y-AABD was retained by DAbR1-positive T cells while it continuously cleared from normal tissues, allowing for in vivo tracking of intravenously administered CAR T cells. Normal-organ dose estimates were favorable for repeated PET/CT studies. Selective T cell ablation in vivo with 177Lu-AABD seems feasible for clustered T-cell populations. Conclusion: We have demonstrated for the first time that T cells can be modified with DAbR1, enabling their in vivo tracking via PET and SPECT. The favorable biodistribution and high image contrast observed warrant further studies of this new reporter gene.
引用
- Krebs S, Ahad A, Carter LM, et al. Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. J Nucl Med. 2018. PMID: 29903928. doi:10.2967/jnumed.118.208041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。